Stifel Hires Dae Gon Ha as Director Covering Biotech Sector
Stifel Financial Corp. (NYSE: SF) has appointed Dae Gon Ha, Ph.D., as Director and Equity Research Analyst for the biotechnology sector, based in Boston. Previously a Vice President at BTIG and SVB Leerink, Dr. Ha brings extensive experience in biotechnology research, particularly in rare diseases. His addition aims to enhance Stifel's healthcare research capabilities, which currently boasts a 52-member team covering 235 companies. This strategic move is aligned with the firm's commitment to providing expert analysis in the growing biotech market.
- Dae Gon Ha's experience in biotechnology research could strengthen Stifel's analysis capabilities.
- The appointment expands Stifel's global research team in the healthcare sector to 52 professionals.
- Potential concerns about continuity and integration within the team due to recent leadership changes.
ST. LOUIS, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that Dae Gon Ha, Ph.D., has joined the firm as a Director and Equity Research Analyst covering the biotechnology sector. He is based in the firm’s Boston office.
Dr. Ha most recently served as a Vice President in biotechnology research at BTIG. Prior to BTIG, he was Vice President in biotechnology research at SVB Leerink, where he focused on rare disease companies. Dr. Ha completed his post-doctoral research fellowship at Harvard Medical School, where he initiated, designed, and executed a chemical compound screen with the goal of identifying novel antibiotics. He received a Ph.D. in Microbiology and Immunology from Dartmouth College and a B.A. in Biology from Grinnell College.
“We are thrilled to welcome Dae Gon to Stifel, as we continue to extend our leading biotech franchise,” said Keith Gay, Director of Research. “Innovation and investment into next-generation medicines and therapies have never been more important or appreciated, and we are dedicated to providing clients with expert analysis and actionable ideas in this key sector.”
Dr. Ha will help strengthen Stifel’s research presence in the rapidly growing healthcare sector, which is currently the second largest sector in the S&P 500. With this hire, Stifel has a global research team of 52 healthcare professionals, including 19 senior analysts, covering 235 companies within the biotechnology, healthcare providers, medical technology & supplies, and specialty pharmaceutical subsectors.
Stifel Company Information
Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC and Century Securities Associates, Inc. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services. To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit https://www.stifel.com/investor-relations/press-releases.
Media Contacts
Neil Shapiro, (212) 271-3447
shapiron@stifel.com
Jeff Preis, (212) 271-3749
preisj@stifel.com
FAQ
What is the significance of Dae Gon Ha's appointment at Stifel Financial Corp.?
How does Stifel Financial Corp. plan to utilize Dae Gon Ha's expertise?
What impact does the new hire have on Stifel Financial Corp.'s research team?
What was Dr. Ha's previous position before joining Stifel Financial Corp.?
